Company to Develop First-in-Class Galectin-3 Inhibitor, GCS-100, for Organ Failure and Cancer
Report Cites the Potential of GCS-100 in Multiple Indications
Available for Download at www.lifesciadvisors.com/clients/lajolla/
NEW YORK, NY – April 25, 2012 – LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of La Jolla Pharmaceutical Company, Inc. (OTC: LJPC.PK), a leading biotechnology company dedicated to developing galectin antagonists for the treatment of major life threatening diseases including chronic organ failure and cancer. The prospects of the Company’s lead asset, GCS-100, are highlighted in the initiation report with a particular focus on the treatment of renal insufficiency and related fibrotic disorders.
“There has been a recent explosion in scientific evidence establishing galectin-3 as a causative or culprit biomarker in organ fibrosis, which leads to organ failure. Specifically, it is now known that galectin-3 plays a key role in the progression of renal, hepatic and cardiac fibrosis,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “As an agent capable of selectively inhibiting galectin-3, GCS-100 could provide a significant therapeutic benefit for patients suffering from all of these diseases.”
In January 2012, La Jolla Pharmaceutical Company acquired worldwide development and commercialization rights to GCS-100, a potent and selective inhibitor of galectin-3 and gained the seasoned management team from Solana Therapeutics.
In an Initiation Report by LifeSci Advisors, we explain the scientific basis and prospects for La Jolla Pharmaceutical Company’s GCS-100. GCS-100 has been administered to over 140 patients in nine Phase 1 and Phase 2 clinical trials and has been shown to be well tolerated at therapeutically relevant doses. It has shown promising activity against a variety of cancers, including chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and renal cell carcinoma (RCC). While GCS-100 still represents a potentially new and important treatment for cancer, La Jolla Pharmaceutical Company intends to explore several other non-cancer development opportunities, including those opportunities related to fibrosis organ failure, which have recently come to light. Specifically, LJPC intends to first evaluate weekly doses of GSC-100 in patients with cancer who have renal insufficiency.
Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.
About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company’s website, www.lifesciadvisors.com.
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report’s full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA’s judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.